News >

Binimetinib/Encorafenib Combo Approaches European Approval for BRAF+ Melanoma

Jason M. Broderick @jasoncology
Published: Friday, Jul 27, 2018

Ron Squarer

Ron Squarer
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the combination of the BRAF inhibitor encorafenib (Braftovi) and the MEK inhibitor binimetinib (Mektovi) for the treatment of adult patients with BRAF V600–mutant unresectable or metastatic melanoma, according to Array BioPharma, the company developing the regimen.

The 2-year OS rates were 58% versus 43% and the 3-year OS rates were 47% versus 32% with COMBO450 versus single-agent vemurafenib, respectively. The OS benefit with the combination was maintained across all subgroups including those defined by sex, age, BRAF status, LDH level, tumor stage, and number of organs involved at baseline.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication